Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: TERN601
TERN-601 was an investigational oral small-molecule GLP-1 receptor agonist evaluated in Phase 1 and Phase 2 clinical studies in adults with overweight or obesity. Clinical studies reported GLP-1-consistent pharmacodynamic effects, including reduced appetite and delayed gastric emptying, together with dose-dependent weight loss. Terns Pharmaceuticals announced in October 2025 that it would not advance TERN-601 after Phase 2 findings, including treatment discontinuations related to adverse events and liver-enzyme elevations.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Clinical study regimens included once-daily oral administration. In the Phase 2 FALCON study, reported dose groups included 250 mg, 500 mg with slower titration, 500 mg, and 750 mg, administered over 12 weeks. These are historical research-study regimens and are not prescribing or administration recommendations. TERN-601 development was discontinued and the compound is not an approved medicine.
Supplementary research context only. Not medical advice or a treatment recommendation.
Development code: TERN-601. Publicly reviewed authoritative sources did not provide a CAS Registry Number, chemical name, molecular formula, molecular weight, SMILES, InChI, or other structure-based identifier.
The Phase 2 FALCON study was a randomized, double-blind, placebo-controlled study of orally administered TERN-601 in adults with overweight or obesity. The study enrolled 167 participants and was completed in September 2025. Publicly reported Phase 2 results included maximum placebo-adjusted weight loss of 4.6% at Week 12; asymptomatic, reversible grade 3 liver-enzyme elevations occurred in three participants during post-treatment follow-up, with two considered drug-related.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention TERN-601 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.